Drug Trial News

RSS

Trial shows no benefit of prescribing an opioid for people with acute back or neck pain

Opioid pain-relieving medicines are not more effective than a placebo in relieving acute back and neck pain and may even cause harm, according to a world-first trial led by the University of Sydney.

28 Jun 2023

New drug effective as a treatment against ulcerative colitis, clinical trial shows

A new drug, investigated by Amsterdam UMC together with colleagues around the world, is effective as a treatment against ulcerative colitis.

28 Jun 2023

New hope for cystic fibrosis patients as groundbreaking treatment enters clinical trial

Clinical testing is underway for a potentially groundbreaking new treatment for cystic fibrosis. Pioneered by scientists at Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign and the Carver College of Medicine at the University of Iowa in partnership with the spin-out biotechnology company, cystetic Medicines, this promising inhalable molecular prosthetic is intended to improve lung function in people with CF who cannot benefit from current therapies.

26 Jun 2023

First successful Phase 2 trial uses cutting-edge RNA CAR-T therapy to treat autoimmunity

Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.

22 Jun 2023

Do Panax notoginseng saponins (Xuesaitong soft capsules) improve function in patients with ischemic stroke?

Researchers examined the effectiveness and safety of using Panax notoginseng saponins for ischemic stroke in adults.

22 Jun 2023

Phase I clinical study of TCR NK cell therapy for sarcoma expected to commence later this year

The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a 'safe to proceed' for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.

20 Jun 2023

Adagrasib shows promise for the treatment of patients with KRAS G12C-mutated non-small cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer.

16 Jun 2023

Phase 3 clinical trial shows favorable safety and immunogenicity profile of single-shot live-attenuated chikungunya vaccine

Researchers performed a double-blinded, phase III randomized trial.

15 Jun 2023

Repeat intraocular corticosteroid injections improve vision in people with persistent or recurrent uveitic macular edema

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a clinical trial funded by the National Eye Institute.

13 Jun 2023

Letermovir: A promising breakthrough in CMV prevention for kidney transplant recipients

In a recent article published in the journal JAMA Network, researchers performed a randomized clinical trial (RCT) to demonstrate the noninferiority of letermovir vs. valganciclovir for prophylaxis of cytomegalovirus (CMV) in adult CMV-seronegative kidney transplant recipients (KTRs) who received a kidney from a CMV-seropositive individual.

13 Jun 2023

VLA1553 vaccine candidate for chikungunya disease produces an immune response in a phase 3 trial

The VLA1553 vaccine candidate for chikungunya disease was generally well tolerated and produced an immune response in 99% (263/266) of participants, according to a phase 3 randomized controlled trial published in The Lancet.

12 Jun 2023

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Humanigen, Inc.today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations.

9 Jun 2023

Study may help advance data on oncolytic adenovirus mediated double suicide-gene therapy for high-grade brain tumors

Researchers in the Hermelin Brain Tumor Center at Henry Ford Health are leading a Phase I clinical trial studying the maximum tolerated dose of an oncolytic adenovirus, a mutated virus engineered to selectively replicate in and destroy cancer tissue, in combination with fractionated stereotactic radiosurgery among patients who are undergoing resection of a recurrent high-grade astrocytoma brain tumor.

8 Jun 2023

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

A first-in-class drug engineered to selectively inhibit the signaling pathway of the cannabinoid receptor shows promise as a safe and effective treatment for cannabis use disorder (CUD), a condition where a person is unable to control their cannabis use, even though it's causing problems in their lives.

8 Jun 2023

Targeted therapy for non-small cell lung cancer provides benefit to patients after surgery

A clinical trial led by Yale Cancer Center shows that the drug osimertinib, a targeted therapy for non-small cell lung cancer, improved rates of survival and reduced risk of recurrence in patients after surgery.

7 Jun 2023

Electronic health records identified as hidden source of bias impacting clinical trials

Results of clinical trials are only as good as the data upon which they rest. This is especially true in terms of diversity - if most people in a trial are from a certain race or socioeconomic group, then the results may not be broadly applicable.

7 Jun 2023

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically associated with poor outcomes, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

7 Jun 2023

Oral semaglutide outperforms other medications in type 2 diabetes treatment, significantly reducing HbA1c and body weight

Orally administered semaglutide shows significant efficacy in reducing HbA1c and body weight in patients with type 2 diabetes compared to other treatments. The study includes a large number of participants from multiple trials.

7 Jun 2023

Study assesses the safety, efficacy of using immune checkpoint inhibitors in patients with advanced kidney cancer

Patients with advanced kidney cancer are routinely given immune checkpoint inhibitors (ICIs) as first-line treatment.

5 Jun 2023

HER2-targeted antibody drug conjugate shows encouraging responses, long-lasting clinical benefit in several tumor types

In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types.

5 Jun 2023

Previous
1
...
37
38
39
40
41
42
43
...
1162
Next

Drug Trial News

Trial shows no benefit of prescribing an opioid for people with acute back or neck pain

New drug effective as a treatment against ulcerative colitis, clinical trial shows

New hope for cystic fibrosis patients as groundbreaking treatment enters clinical trial

First successful Phase 2 trial uses cutting-edge RNA CAR-T therapy to treat autoimmunity

Do Panax notoginseng saponins (Xuesaitong soft capsules) improve function in patients with ischemic stroke?

Phase I clinical study of TCR NK cell therapy for sarcoma expected to commence later this year

Adagrasib shows promise for the treatment of patients with KRAS G12C-mutated non-small cell lung cancer

Phase 3 clinical trial shows favorable safety and immunogenicity profile of single-shot live-attenuated chikungunya vaccine

Repeat intraocular corticosteroid injections improve vision in people with persistent or recurrent uveitic macular edema

Letermovir: A promising breakthrough in CMV prevention for kidney transplant recipients

VLA1553 vaccine candidate for chikungunya disease produces an immune response in a phase 3 trial

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Study may help advance data on oncolytic adenovirus mediated double suicide-gene therapy for high-grade brain tumors

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

Targeted therapy for non-small cell lung cancer provides benefit to patients after surgery

Electronic health records identified as hidden source of bias impacting clinical trials

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

Oral semaglutide outperforms other medications in type 2 diabetes treatment, significantly reducing HbA1c and body weight

Study assesses the safety, efficacy of using immune checkpoint inhibitors in patients with advanced kidney cancer

HER2-targeted antibody drug conjugate shows encouraging responses, long-lasting clinical benefit in several tumor types

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News